JP2023516067A5 - - Google Patents

Info

Publication number
JP2023516067A5
JP2023516067A5 JP2022552528A JP2022552528A JP2023516067A5 JP 2023516067 A5 JP2023516067 A5 JP 2023516067A5 JP 2022552528 A JP2022552528 A JP 2022552528A JP 2022552528 A JP2022552528 A JP 2022552528A JP 2023516067 A5 JP2023516067 A5 JP 2023516067A5
Authority
JP
Japan
Prior art keywords
region
heavy chain
light chain
seq
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022552528A
Other languages
English (en)
Japanese (ja)
Other versions
JP7834345B2 (ja
JP2023516067A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/020511 external-priority patent/WO2021178430A2/en
Publication of JP2023516067A publication Critical patent/JP2023516067A/ja
Publication of JP2023516067A5 publication Critical patent/JP2023516067A5/ja
Application granted granted Critical
Publication of JP7834345B2 publication Critical patent/JP7834345B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022552528A 2020-03-02 2021-03-02 がんの処置のためのキメラ抗原受容体ならびに関連した方法および組成物 Active JP7834345B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062984139P 2020-03-02 2020-03-02
US62/984,139 2020-03-02
US202063084138P 2020-09-28 2020-09-28
US63/084,138 2020-09-28
PCT/US2021/020511 WO2021178430A2 (en) 2020-03-02 2021-03-02 Chimeric antigen receptors and related methods and compositions for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2023516067A JP2023516067A (ja) 2023-04-17
JP2023516067A5 true JP2023516067A5 (cg-RX-API-DMAC7.html) 2024-03-06
JP7834345B2 JP7834345B2 (ja) 2026-03-24

Family

ID=77613112

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022552528A Active JP7834345B2 (ja) 2020-03-02 2021-03-02 がんの処置のためのキメラ抗原受容体ならびに関連した方法および組成物

Country Status (8)

Country Link
US (2) US12595311B2 (cg-RX-API-DMAC7.html)
EP (1) EP4114861A4 (cg-RX-API-DMAC7.html)
JP (1) JP7834345B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220149606A (cg-RX-API-DMAC7.html)
CN (1) CN115551891A (cg-RX-API-DMAC7.html)
AU (1) AU2021232512A1 (cg-RX-API-DMAC7.html)
CA (1) CA3174575A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021178430A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
KR20250067749A (ko) * 2023-11-07 2025-05-15 주식회사 박셀바이오 EphA2를 타겟하는 개선된 특성을 갖는 친수성 모노바디 및 이를 포함하는 다중특이적 키메라 항원 수용체 및 조작된 면역세포
WO2026096570A1 (en) * 2024-10-30 2026-05-07 Pluto Immunotherapeutics, Inc. Hybrid anti-cd20 car t cell therapy for the treatment of autoimmune diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050037420A1 (en) * 2001-09-14 2005-02-17 Mei-Yun Zhang Immunoglobulin having particular framework scaffold and methods of making and using
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
AU2017235657B2 (en) 2016-03-18 2022-07-21 Fred Hutchinson Cancer Center Compositions and methods for CD20 immunotherapy
US20190112380A1 (en) 2016-03-29 2019-04-18 University Of Southern California Chimeric antigen receptors targeting cancer
CN117298260A (zh) 2016-09-02 2023-12-29 莱蒂恩技术公司 用DuoCAR治疗癌症的组合物和方法
EP3529268B1 (en) 2016-10-19 2025-02-26 The Scripps Research Institute Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
WO2018200582A1 (en) 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Chimeric antibody/t-cell receptor constructs and uses thereof
CA3069527A1 (en) 2017-07-12 2019-01-17 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for treatment of cancers harboring an h3k27m mutation
BR112020005938A2 (pt) 2017-09-27 2020-11-17 University Of Southern California célula imune ou população de células imunes da mesma, célula efetora imune ou célula-tronco, célula que apresenta antígeno, polinucleotídeo recombinante, vetor, composição que compreende uma célula imune efetora ou uma célula-tronco, métodos para produzir uma célula efetora imune que expressa receptor imune de ocorrência não natural, para gerar uma população de células manipuladas por rna, para fornecer imunidade antidoença em um indivíduo, para tratar ou prevenir uma doença associada à expressão de um antígeno, e, uso
AU2020232789B2 (en) * 2019-03-06 2026-04-09 Lentigen Technology, Inc. Compositions and methods for treating cancer with self-driving chimeric antigen receptors
IL305175A (en) * 2021-02-19 2023-10-01 Angeles Therapeutics Inc Single-chain and multi-chain synthetic antigen receptors for diverse immune cells

Similar Documents

Publication Publication Date Title
TWI899054B (zh) 治療癌症及增強t細胞重定向治療劑之功效的方法(一)
CN112673022B (zh) 针对cd33的单结构域抗体及其构建体
JP7573441B2 (ja) ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法
US12534532B2 (en) CLL1-targeting antibody and application thereof
JP2022002546A (ja) 細胞
IL312206A (en) Preparations and methods for selective protein expression
JP2022548778A5 (cg-RX-API-DMAC7.html)
TW201904997A (zh) 引導及導航控制蛋白質以及彼之製造及使用方法
CA3032054A1 (en) Combination therapies of chimeric antigen receptors and pd-1 inhibitors
CN116829194A (zh) 用于工程化细胞疗法的靶向细胞因子构建体
CA3131016A1 (en) Multifunctional molecules that bind to calreticulin and uses thereof
US20230257475A1 (en) Multispecific chimeric antigen receptors and uses thereof
JP2025066746A (ja) 抗adam12抗体およびキメラ抗原受容体、ならびにそれを含む組成物および方法
WO2023202280A1 (zh) 抗B7H6的scFv抗体、其编码基因及其应用
JP2024105603A (ja) CARライブラリおよびscFvの製造方法
KR20210111244A (ko) 태반-유래 동종이계 car-t 세포 및 이의 용도
WO2023217062A1 (zh) 一种嵌合抗原受体及其应用
WO2025140265A1 (en) Combination of chimeric antigen receptor and dap10 in cell therapy
CN117957246A (zh) Mog结合蛋白和其用途
TW202309294A (zh) 病毒載體生產系統
TW202434636A (zh) 抗原結合域及其使用方法
JP2022546590A5 (cg-RX-API-DMAC7.html)
JP2025540909A (ja) 免疫療法のためのcd3発現及びキメラ抗原受容体の遮断
KR20260036568A (ko) 세포 면역 요법용 조성물, 및 방법
WO2024151213A2 (en) Blockade of cd8 expression and chimeric antigen receptors for immunotherapy of t-cell and nk-cell malignancies